There were no differences in circulating CD16+CD56+ NK cells between the healthy group and stage I or II CRC group (p = 0.38 and p = 0.28, respectively), but significant differences exist between the healthy group and stage III or IV CRC group (p < 0.01, p < 0.01, and p < 0.001, respectively, Table 1). This evidence concerns the gene NCAM1 and colorectal carcinoma.